ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

47 links1 made here, not in the record95 judgments2 judges (the rules as one: Rule based)0 record changes seen
Claude Opus 5.5Rule basedReplaced, or read an older versionMade here
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT01042379I-SPY TRIAL: Neoadjuvantand Personalized AdaptiveNovel Agents to TreatBreast CancerQuantumLeap Healthcare CollaboPhase 2 · recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›No new version seen since tracking began Sep 25, 2026.CONDITIONSBreast NeoplasmsThe registry's MeSH filing›No judgment recorded. Shown as the registry files it.HemangiosarcomaThe registry's MeSH filing›No judgment recorded. Shown as the registry files it.Triple Negative Breast Neop…The registry's MeSH filing›As of now · Rule based · Main conditionMain conditionNeoplasmsThe registry's MeSH filing›No judgment recorded. Shown as the registry files it.Pathologic Complete ResponseThe registry's MeSH filing›No judgment recorded. Shown as the registry files it.DRUGSTrebananibEntry “AMG 386 with or without Trastu…›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · TestedBackgroundTrastuzumabEntry “AMG 386 with or without Trastu…›Nov 2 · Claude Opus 5.5 · BackgroundNov 10 · Claude Opus 5.5 · Tested · partnerNov 18 · Rule based · TestedTested · partnerGanitumabEntry “AMG 479 (Ganitumab) plus Metfo…›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · ComparatorTestedMK 2206Entry “MK-2206 with or without Trastu…›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · TestedBackgroundAdo-Trastuzumab EmtansineEntry “T-DM1 and Pertuzumab”, read by…›Nov 2 · Claude Opus 5.5 · TestedNov 10 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedPertuzumabEntry “T-DM1 and Pertuzumab”, read by…›Nov 2 · Claude Opus 5.5 · TestedNov 10 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedINT009718Entry “Pertuzumab and Trastuzumab”, r…›Nov 2 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · ComparatorComparatorSTA 9090Entry “Ganetespib”, read by our name …›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedVeliparibEntry “ABT-888”, read by our name rule›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · ComparatorTestedNeratinibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · ComparatorTestedPexidartinibEntry “PLX3397”, read by our name rule›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedPembrolizumabEntry “Pembrolizumab - 4 cycle”, read…›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedTalazoparibEntry “Talazoparib plus Irinotecan”, …›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedIrinotecanEntry “Talazoparib plus Irinotecan”, …›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedPatritumabEntry “Patritumab and Trastuzumab”, r…›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · TestedBackgroundSGN-LIV1AIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedDurvalumabEntry “Durvalumab plus Olaparib”, rea…›Nov 2 · Claude Opus 5.5 · TestedNov 10 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedOlaparibEntry “Durvalumab plus Olaparib”, rea…›Nov 2 · Claude Opus 5.5 · TestedNov 10 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedNelitolimodEntry “SD-101 + Pembrolizumab”, read …›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedTucatinibEntry “Tucatinib plus trastuzumab and…›Nov 2 · Claude Opus 5.5 · BackgroundNov 10 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedCemiplimabIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedFianlimabEntry “Cemiplimab plus REGN3767”, rea…›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedTrilaciclibEntry “Trilaciclib with or without tr…›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · TestedBackgroundTrastuzumab duocarmazineEntry “SYD985 ([vic-]trastuzumab duoc…›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedDostarlimabEntry “Oral Paclitaxel + Encequidar +…›Nov 2 · Claude Opus 5.5 · TestedNov 10 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · TestedBackground · partnerAmcenestrantIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedAbemaciclibEntry “Amcenestrant + Abemaciclib”, r…›Nov 2 · Claude Opus 5.5 · TestedNov 10 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · TestedTestedLetrozoleEntry “Amcenestrant + Letrozole”, rea…›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedARX788Intervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedDatopotamab deruxtecanIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 10 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedZanidatamabIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedLasofoxifeneIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedEndoxifenEntry “Z-endoxifen”, read by our name…›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedVepdegestrantEntry “ARV-471”, read by our name rule›Nov 2 · Claude Opus 5.5 · TestedNov 10 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedRilvegostomigEntry “Rilvegostomig + TDXd”, read by…›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedINT011326Entry “Dan222 + Niraparib”, read by o…›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedNiraparibEntry “Dan222 + Niraparib”, read by o…›Nov 2 · Claude Opus 5.5 · TestedNov 10 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedSarilumabEntry “Sarilumab + Cemiplimab + Pacli…›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedPaclitaxelEntry “Sarilumab + Cemiplimab + Pacli…›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedMocertatug rezetecanEntry “GSK 5733584”, read by our name…›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedIvonescimabEntry “Ivonescimab (20mg/kg Q3W)”, re…›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedTrastuzumab deruxtecanMade here · Found by reading; no entr…›Nov 10 · Claude Opus 5.5 · Background · partnerBackground · partner

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Trebananib

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “AMG 386 with or without Trastuzumab”the record gives no role
→judged→changed
How the 2 judgments split50%of judgments with a known value say Background
Background · 1
Tested · 1

All judgments on this study

WhenLinkJudgeDecisionState
Nov 2TrebananibClaude Opus 5.5BackgroundCurrent
Nov 2TrastuzumabClaude Opus 5.5BackgroundReplaced
Nov 2GanitumabClaude Opus 5.5TestedCurrent
Nov 2MK 2206Claude Opus 5.5BackgroundCurrent
Nov 2Ado-Trastuzumab EmtansineClaude Opus 5.5TestedReplaced
Nov 2PertuzumabClaude Opus 5.5TestedReplaced
Nov 2INT009718Claude Opus 5.5ComparatorCurrent
Nov 2STA 9090Claude Opus 5.5TestedCurrent
Nov 2VeliparibClaude Opus 5.5TestedCurrent
Nov 2NeratinibClaude Opus 5.5TestedCurrent
Nov 2PexidartinibClaude Opus 5.5TestedCurrent
Nov 2PembrolizumabClaude Opus 5.5TestedCurrent
Nov 2TalazoparibClaude Opus 5.5TestedCurrent
Nov 2IrinotecanClaude Opus 5.5TestedCurrent
Nov 2PatritumabClaude Opus 5.5BackgroundCurrent
Nov 2SGN-LIV1AClaude Opus 5.5TestedCurrent
Nov 2DurvalumabClaude Opus 5.5TestedReplaced
Nov 2OlaparibClaude Opus 5.5TestedReplaced
Nov 2NelitolimodClaude Opus 5.5TestedCurrent
Nov 2TucatinibClaude Opus 5.5BackgroundReplaced
Nov 2CemiplimabClaude Opus 5.5TestedCurrent
Nov 2FianlimabClaude Opus 5.5TestedCurrent
Nov 2TrilaciclibClaude Opus 5.5BackgroundCurrent
Nov 2Trastuzumab duocarmazineClaude Opus 5.5TestedCurrent
Nov 2DostarlimabClaude Opus 5.5TestedReplaced
Nov 2AmcenestrantClaude Opus 5.5TestedCurrent
Nov 2AbemaciclibClaude Opus 5.5TestedReplaced
Nov 2LetrozoleClaude Opus 5.5TestedCurrent
Nov 2ARX788Claude Opus 5.5TestedCurrent
Nov 2Datopotamab deruxtecanClaude Opus 5.5TestedReplaced
Nov 2ZanidatamabClaude Opus 5.5TestedCurrent
Nov 2LasofoxifeneClaude Opus 5.5TestedCurrent
Nov 2EndoxifenClaude Opus 5.5TestedCurrent
Nov 2VepdegestrantClaude Opus 5.5TestedReplaced
Nov 2RilvegostomigClaude Opus 5.5TestedCurrent
Nov 2INT011326Claude Opus 5.5TestedCurrent
Nov 2NiraparibClaude Opus 5.5TestedReplaced
Nov 2SarilumabClaude Opus 5.5TestedCurrent
Nov 2PaclitaxelClaude Opus 5.5TestedCurrent
Nov 2Mocertatug rezetecanClaude Opus 5.5TestedCurrent
Nov 2IvonescimabClaude Opus 5.5TestedCurrent
Nov 10TrastuzumabClaude Opus 5.5Tested · partnerCurrent
Nov 10PertuzumabClaude Opus 5.5TestedCurrent
Nov 10DurvalumabClaude Opus 5.5TestedCurrent
Nov 10OlaparibClaude Opus 5.5TestedCurrent
Nov 10TucatinibClaude Opus 5.5TestedCurrent
Nov 10AbemaciclibClaude Opus 5.5Background · partnerCurrent
Nov 10Datopotamab deruxtecanClaude Opus 5.5TestedCurrent
Nov 10VepdegestrantClaude Opus 5.5TestedCurrent
Nov 10NiraparibClaude Opus 5.5TestedCurrent
Nov 10Trastuzumab deruxtecanmade hereClaude Opus 5.5Background · partnerCurrent
Nov 10Ado-Trastuzumab EmtansineClaude Opus 5.5TestedCurrent
Nov 10DostarlimabClaude Opus 5.5Background · partnerCurrent
Nov 18TrebananibRule based · role ruleTestedOverridden
Nov 18TrastuzumabRule based · role ruleTestedOverridden
Nov 18GanitumabRule based · role ruleComparatorOverridden
Nov 18MK 2206Rule based · role ruleTestedOverridden
Nov 18Ado-Trastuzumab EmtansineRule based · role ruleTestedAgrees
Nov 18PertuzumabRule based · role ruleTestedAgrees
Nov 18INT009718Rule based · role ruleComparatorAgrees
Nov 18STA 9090Rule based · role ruleTestedAgrees
Nov 18VeliparibRule based · role ruleComparatorOverridden
Nov 18NeratinibRule based · role ruleComparatorOverridden
Nov 18PexidartinibRule based · role ruleTestedAgrees
Nov 18PembrolizumabRule based · role ruleTestedAgrees
Nov 18TalazoparibRule based · role ruleTestedAgrees
Nov 18IrinotecanRule based · role ruleTestedAgrees
Nov 18PatritumabRule based · role ruleTestedOverridden
Nov 18SGN-LIV1ARule based · role ruleTestedAgrees
Nov 18DurvalumabRule based · role ruleTestedAgrees
Nov 18OlaparibRule based · role ruleTestedAgrees
Nov 18NelitolimodRule based · role ruleTestedAgrees
Nov 18TucatinibRule based · role ruleTestedAgrees
Nov 18CemiplimabRule based · role ruleTestedAgrees
Nov 18FianlimabRule based · role ruleTestedAgrees
Nov 18TrilaciclibRule based · role ruleTestedOverridden
Nov 18Trastuzumab duocarmazineRule based · role ruleTestedAgrees
Nov 18DostarlimabRule based · role ruleTestedOverridden
Nov 18AmcenestrantRule based · role ruleTestedAgrees
Nov 18AbemaciclibRule based · role ruleTestedCurrent
Nov 18LetrozoleRule based · role ruleTestedAgrees
Nov 18ARX788Rule based · role ruleTestedAgrees
Nov 18Datopotamab deruxtecanRule based · role ruleTestedAgrees
Nov 18ZanidatamabRule based · role ruleTestedAgrees
Nov 18LasofoxifeneRule based · role ruleTestedAgrees
Nov 18EndoxifenRule based · role ruleTestedAgrees
Nov 18VepdegestrantRule based · role ruleTestedAgrees
Nov 18RilvegostomigRule based · role ruleTestedAgrees
Nov 18INT011326Rule based · role ruleTestedAgrees
Nov 18NiraparibRule based · role ruleTestedAgrees
Nov 18SarilumabRule based · role ruleTestedAgrees
Nov 18PaclitaxelRule based · role ruleTestedAgrees
Nov 18Mocertatug rezetecanRule based · role ruleTestedAgrees
Nov 18IvonescimabRule based · role ruleTestedAgrees
As of nowTriple Negative Breast NeoplasmsRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.